Reference is made to the stock exchange release published by Arctic Bioscience 21 April 2023 regarding the Annual General Meeting’s approval of share capital increase and corresponding issuance of new shares in Arctic Bioscience.
The share capital increase has now been registered with the Norwegian Register of Business Enterprises. As a result, the new share capital of Arctic Bioscience has increased from NOK 2 442 571,90 to NOK 2 536 955,20, divided into 25 369 552 shares, each having a nominal value of NOK 0,10.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Act.
For more information, please contact:
Christer L. Valderhaug
Phone: +47 920 84 601
About Arctic Bioscience
Arctic Bioscience is a biotech company developing and commercializing pharmaceutical and nutraceutical products based on unique bioactive marine compounds.
The company is developing HRO350 – a novel investigational drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. This is a large patient group in need of new effective medicines with beneficial safety profile.
Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as well as finished goods under the ROMEGA® brand.
Arctic Bioscience is led by a team of highly competent people with experience in developing marine oils and experience from global pharmaceutical companies.